AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
06 août 2024 07h00 HE
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
31 juil. 2024 08h30 HE
|
AC Immune SA
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 morADC combines proprietary brain-penetrant small...
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease
25 juil. 2024 07h00 HE
|
AC Immune SA
AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease Treatment of first randomized person with preclinical AD expected this quarterPhase 2b ReTain...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
16 juil. 2024 07h00 HE
|
AC Immune SA
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s...
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
28 mai 2024 07h00 HE
|
AC Immune SA
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company...
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
13 mai 2024 06h05 HE
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
13 mai 2024 06h00 HE
|
AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14 mars 2024 07h00 HE
|
AC Immune SA
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
22 févr. 2024 07h00 HE
|
AC Immune SA
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to...
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22 janv. 2024 07h00 HE
|
AC Immune SA
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapiesActive immunotherapy now...